Alex Goldsmith
Endocrinology, Diabetes & Metabolism · Denver, CONPI 1417907064
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.9% of the total across 667 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 59 manufacturers, the largest accounting for just 12.5% — the pattern of someone who eats at a lot of different presentations.
Across 667 payments — averaging $18.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Amgen$1K
- Novo Nordisk$1K
- Lilly USA, LLC$807
- AstraZeneca$700
- Pfizer$603
- plus $7K from 53 others
What the payments were for
- Food & beverage$12,32299%
- Education$1391%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$120
How this compares
$12,461 in reported general payments places this provider in the 80th percentile of 120 endocrinology, diabetes & metabolism providers in Colorado.
See all endocrinology, diabetes & metabolism providers in Colorado →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 165 | $152,288 |
| MounjaroTirzepatide | 98 | $105,852 |
| Repatha SureclickEvolocumab | 125 | $92,784 |
| OzempicSemaglutide | 46 | $52,599 |
| LinzessLinaclotide | 37 | $30,909 |
| MyrbetriqMirabegron | 33 | $29,340 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 34 | $27,868 |
| JardianceEmpagliflozin | 24 | $23,769 |
| GemtesaVibegron | 22 | $21,938 |
| CaplytaLumateperone Tosylate | 12 | $19,449 |
| XareltoRivaroxaban | 12 | $16,092 |
| RybelsusSemaglutide | 13 | $14,656 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 12 | $14,310 |
| ZenpepLipase/Protease/Amylase | 16 | $14,005 |
| SynthroidLevothyroxine Sodium | 119 | $12,199 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $603 | $152,288165 claims |
| Lilly USA, LLCMounjaro | $807 | $105,85298 claims |
| Novo NordiskOzempic, Rybelsus | $1,048 | $67,25559 claims |
| AbbVieLinzess, Synthroid, Viberzi, Restasis | $1,559 | $59,311179 claims |
| GSKTrelegy Ellipta, Arexvy, Shingrix | $405 | $40,64279 claims |
| Astellas Pharma US IncMyrbetriq, Veozah | $564 | $36,59646 claims |
| Boehringer IngelheimJardiance, Synjardy | $294 | $27,76137 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $127 | $21,93822 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $700 | $20,17930 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $466 | $19,44912 claims |
| Johnson & JohnsonXarelto | $373 | $16,09212 claims |
| Aimmune Therapeutics, Inc.Zenpep | $33 | $14,00516 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 120 endocrinology, diabetes & metabolism providers in Colorado.
Other endocrinology, diabetes & metabolism in Denver
- Daniel BessesenDenver$34K
- Michael LoughnerDenver$32K
- Leonard ZemelDenver$19K
- Daniel CitronDenver$8K
- Sarah BullDenver$4K
- Leslie GamacheDenver$4K
- Claudia PanzerDenver$3K
- Sheila MaierDenver$2K
- Karin HickeyDenver$2K
- Gregory LundDenver$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.